Denali Therapeutics
DNLI
197 hedge funds and large institutions have $2.93B invested in Denali Therapeutics in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 86 increasing their positions, 52 reducing their positions, and 28 closing their positions.
616% more call options, than puts
Call options by funds: $1.93M | Put options by funds: $270K
65% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 52
2.63% more ownership
Funds ownership: 74.94% → 77.56% (+2.6%)
3% more capital invested
Capital invested by funds: $2.84B → $2.93B (+$93.1M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 28
2% less funds holding
Funds holding: 200 → 197 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$152M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$64.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46M |
| 4 |
Temasek Holdings
Singapore
|
+$28M |
| 5 |
DM
Deerfield Management
New York
|
+$23.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.9M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$13.6M |
| 3 |
CM
Crestline Management
Fort Worth,
Texas
|
-$8.93M |
| 4 |
Morgan Stanley
New York
|
-$7.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.1M |
DNLI Hedge Fund Activity: Q4 2022 in Review
197 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2022, worth a combined $2.93B — up 3.3% from $2.84B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of DNLI and 26 opened new positions — a net loss of 2 holders — while 52 trimmed existing stakes and 86 added.
The largest buyer was Wellington Management Group, adding an estimated $152M. The largest seller was Point72 Asset Management, cutting an estimated $16.9M.
- 197 institutional investors held Denali Therapeutics (DNLI) as of Q4 2022, down from 200 in Q3 2022.
- Funds reported $2.93B of Denali Therapeutics stock for Q4 2022, up 3.3% quarter-over-quarter.
- 26 funds opened new Denali Therapeutics positions in Q4 2022 and 28 closed out, a net change of -2 holders.
- The largest Denali Therapeutics buyer in Q4 2022 was Wellington Management Group, an estimated $152M added.
- The largest Denali Therapeutics seller in Q4 2022 was Point72 Asset Management, an estimated $16.9M sold.
Based on aggregated 13F filings for Q4 2022.